Atlas Trials

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Clinical trial NCT01860937 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT01860937
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed B-Cell Acute Lymphoblastic Leukemia
Start date
2013-05-01
Primary completion
2027-05-01
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.